Cinuperone

Cinuperone

SCHEMBL678891

O=C(CCCN1CCN(c2cc3ccccc3cn2)CC1)c1ccc(F)cc1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 8/20 0.70
DRD2 P14416 8/20 0.70
DRD4 P21917 8/20 0.70
HTR2A P28223 8/20 0.70
DRD3 P35462 8/20 0.70
HTR2C P28335 7/20 0.70
HTR7 P34969 6/20 0.70
TMEM97 Q5BJF2 5/20 0.70
SIGMAR1 Q99720 5/20 0.70
LMNA P02545 1/20 0.70
CYP1A2 P05177 1/20 0.70
CYP3A4 P08684 1/20 0.70
CYP2D6 P10635 1/20 0.70
CYP2C9 P11712 1/20 0.70
CYP2C19 P33261 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.70
HRH1 P35367 2/20 0.64
ADRA2C P18825 1/20 0.64
SLC6A4 P31645 1/20 0.63
ALDH1A1 P00352 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cinuperone SCHEMBL31395265 1.00 HTR1A (0.70) HTR1ADRD2DRD4HTR2ADRD3
SCHEMBL10834325 0.92 DRD2 (0.67) HTR1ADRD2DRD4HTR2ADRD3
SCHEMBL10832658 0.91 HTR1A (0.57) HTR1ADRD2DRD4HTR2ADRD3
SCHEMBL10833658 0.89 HTR1A (0.55) HTR1ADRD2DRD4HTR2ADRD3
SCHEMBL10834159 0.88 DRD2 (0.74) HTR1ADRD2DRD4HTR2ADRD3
SCHEMBL10833626 0.87 HTR1A (0.53) HTR1ADRD2DRD4HTR2ADRD3
SCHEMBL10833664 0.86 DRD2 (0.61) HTR1ADRD2DRD4HTR2ADRD3
SCHEMBL10833527 0.85 HTR2A (0.52) HTR1ADRD2DRD4HTR2ADRD3
SCHEMBL10833345 0.85 DRD2 (0.59) HTR1ADRD2DRD4HTR2ADRD3
SCHEMBL10787321 0.84 DRD2 (0.69) HTR1ADRD2DRD4HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018015915-A1 A PARENTERAL CONTROLLED RELEASE COMPOSITION OF AN ATYPICAL ANTIPSYCHOTIC AGENT CADILA HEALTHCARE LIMITED (IN) 2018-01-25 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
EP-1091759-B1 COMPOSITION FOR THE INDUCTION OF APOPTOSIS IN TARGET CELLS UNIV DUNDEE (GB) 2012-10-24 EP claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-4590273-A NEUROLEPTIC HYPOTENSIVE AND ANTIARRHYTHMIC AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1986-05-20 US claimed
US-12251380-B2 Depot systems comprising cariprazine or salts thereof MAPI PHARMA LTD. (IL) 2025-03-18 US disclosed
EP-4493274-A1 DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF Mapi Pharma Ltd. (IL) 2025-01-22 EP disclosed
US-20240238280-A1 DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF MAPI PHARMA LTD. (IL) 2024-07-18 US disclosed
US-11931357-B2 Depot systems comprising Cariprazine or salts thereof MAPI PHARMA LTD. (IL) 2024-03-19 US disclosed
US-20230293515-A1 DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF MAPI PHARMA LTD. (IL) 2023-09-21 US disclosed
WO-2023175598-A1 DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF MAPI PHARMA LTD. (IL) 2023-09-21 WO disclosed
US-5162341-A Piperidine Derivatives DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-11-10 US disclosed
WO-1992018127-A1 USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-10-29 WO disclosed
WO-1992014463-A1 USE OF SIGMA RECEPTOR ANTAGONISTS FOR TREATMENT OF AMPHETAMINE ABUSE THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-09-03 WO disclosed
WO-1992014464-A1 USE OF SIGMA RECEPTOR ANTAGONISTS FOR TREATMENT OF COCAINE ABUSE THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-09-03 WO disclosed
US-4590273-A NEUROLEPTIC HYPOTENSIVE AND ANTIARRHYTHMIC AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1986-05-20 US disclosed
EP-0047923-B1 ISOQUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1984-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238280-A1 DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF MC2R, CRHR1, MC5R HTR1A 1273/4885DRD2 93/4885DRD4 183/4885
US-12251380-B2 Depot systems comprising cariprazine or salts thereof MC2R, CRHR1, MC5R HTR1A 1273/4885DRD2 93/4885DRD4 183/4885
US-20230293515-A1 DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF MC2R, MC5R, CRHR1 HTR1A 1271/4885DRD2 95/4885DRD4 190/4885
US-11931357-B2 Depot systems comprising Cariprazine or salts thereof MC2R, MC5R, CRHR1 HTR1A 1271/4885DRD2 95/4885DRD4 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.